Eddy Saad

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 4

Top Topics

Replacement Therapy

Metastatic Renal Cell Carcinoma

Optical Coherence Tomography

Top Venues

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting

This page only lists publications with an associated author ORCID identifier.

Publications

Eddy Saad, Georges Gebrael, Karl Semaan, Marc Eid, Renée Maria Saliby, Chris Labaki, Nicolas Sayegh, J Connor Wells, Kosuke Takemura, Matthew Scott Ernst, Audreylie Lemelin, Naveen S Basappa, Lori A Wood, Thomas Powles, D Scott Ernst, Aly-Khan A Lalani, Archana M Agarwal, Wanling Xie, Daniel Y C Heng, Toni K Choueiri
Impact of smoking status on clinical outcomes in patients with metastatic renal cell carcinoma treated with first-line immune checkpoint inhibitor-based regimens. The oncologist (2024)
Eddy Saad, Georges Gebrael, Karl Semaan, Marc Eid, Renée Maria Saliby, Chris Labaki, Nicolas Sayegh, J Connor Wells, Kosuke Takemura, Matthew Scott Ernst, Audreylie Lemelin, Naveen S Basappa, Lori A Wood, Thomas Powles, D Scott Ernst, Aly-Khan A Lalani, Archana M Agarwal, Wanling Xie, Daniel Y C Heng, Toni K Choueiri
Impact of smoking status on clinical outcomes in patients with metastatic renal cell carcinoma treated with first-line immune checkpoint inhibitor-based regimens. The oncologist 29 (8) (2024)
Renee Maria Saliby, Eddy Saad, Soki Kashima, David A Schoenfeld, David A Braun
Update on Biomarkers in Renal Cell Carcinoma. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 44 (2) (2024)
Eddy Saad, Georges Gebrael, Karl Semaan, Marc Eid, Renée Maria Saliby, Chris Labaki, Nicolas Sayegh, J Connor Wells, Kosuke Takemura, Matthew Scott Ernst, Audreylie Lemelin, Naveen S Basappa, Lori A Wood, Thomas Powles, D Scott Ernst, Aly-Khan A Lalani, Archana M Agarwal, Wanling Xie, Daniel Y C Heng, Toni K Choueiri
Impact of smoking status on clinical outcomes in patients with metastatic renal cell carcinoma treated with first-line immune checkpoint inhibitor-based regimens. The oncologist 29 (8) (2024)